Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:CASNumber |
1001264-89-6
|
| gptkbp:developedBy |
GlaxoSmithKline
|
| gptkbp:hasBiologicalActivity |
protease inhibitor
|
| gptkbp:hasMolecularFormula |
C17H13Cl2N3O2S
|
| gptkbp:hasSMILES |
C1=CC=C(C(=C1)Cl)N2C=NN=C2C3=CC=C(C=C3)C(=O)NC4=CC=C(C=C4)Cl
|
| https://www.w3.org/2000/01/rdf-schema#label |
GSK650394
|
| gptkbp:inhibitedBy |
gptkb:SGK1
SGK2 SGK3 |
| gptkbp:IUPACName |
4-chloro-N-(3-(2-chlorophenyl)-1,2,4-thiadiazol-5-yl)benzamide
|
| gptkbp:molecularWeight |
410.28 g/mol
|
| gptkbp:PubChem_CID |
25154715
|
| gptkbp:synonym |
SGK1 inhibitor GSK650394
|
| gptkbp:target |
serum- and glucocorticoid-regulated kinase 1
serum- and glucocorticoid-regulated kinase 2 serum- and glucocorticoid-regulated kinase 3 |
| gptkbp:usedInResearchOn |
gptkb:cancer
inflammation metabolic disorders |
| gptkbp:bfsParent |
gptkb:SGK1
|
| gptkbp:bfsLayer |
7
|